VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

• Conditions: Non Small Cell Lung Cancer; Brain Metastasis

• Registration Number: NCT01891708
• Lead Sponsor: Li Liu

Brief Summary

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Detailed Description

1. non small cell lung cancer (non squamous carcinoma)

2. ECOG 0-1

3. from 18-75 years old

Study Timeline

• Study Start: 2013-06
• Study First Submitted: 2013-06-19
• Status Verified: 2013-07
• Study First Submitted QC: 2013-07-02
• Last Update Submitted: 2013-07-02
• Study First Posted: 2013-07-03
• Last Update Posted: 2013-07-03
• Primary Completion: 2014-12
• Study Completion: 2018-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• non squamous cell non small cell lung cancer
• with measurable disease
• ECOG 0-1

Exclusion Criteria

• patients received surgery in recent 4 weeks

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PFS	6 months

Secondary Outcome Measures

Name	Time	Method
OS	18 months

Trial Locations

Locations (1)

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China